AT A GLANCE

12/17/2021

Coronavirus Disease 2019 (COVID-19)

This update is current as of 3:00 p.m. on the date it was posted.

NEW FREQUENCY ALERT

As of December 6, 2021 this document will be published on Tuesdays and Fridays. This change reflects the current COVID-19 landscape where the situational updates and guidelines are no longer being released daily by the relevant organizations.

This document is a collation of resources for your reference. For official guidance on COVID-19 in Ontario, please visit the Ministry of Health.

Table of Contents

New Content ........................................................................................................................................ 3
Public Health Agencies .......................................................................................................................... 3
  Public Health Agency of Canada | canada.ca .................................................................................. 3
  BC Centre for Disease Control | bccdc.ca .................................................................................. 3
  Institut national de santé publique ............................................................................................... 3
  International (outside of Canada) .................................................................................................... 4
  CDC: Centers for Disease Control and Prevention | cdc.gov .................................................... 4
  ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu ......................... 6
  FDA: U.S. Food & Drug Administration | fda.gov ........................................................................ 6
  Public Health England | gov.uk ........................................................................................................... 6
  World Health Organization | who.int .................................................................................................... 7
  Other relevant government bodies / health care organization ......................................................... 7
  CIDRAP: Center for Infectious Disease Research Policy | cidrap.umn.edu .................................... 9
  National Collaborating Centre for Environmental Health | ncceh.ca .......................................... 9
  ProMED | promedmail.org ............................................................................................................... 9
  Updated Daily .................................................................................................................................. 9
  COVID-19 resources (case counts) | arcgis.com ........................................................................ 9
New Content

Public Health Agencies

Public Health Agency of Canada | canada.ca
Instead of daily case counts and vaccinations, starting the week of December 6, 2021 we will be reporting weekly trends. For daily case counts, you can still check 2019 novel coronavirus: outbreak update, or COVID-19 vaccination in Canada for vaccination rates.

- Canada COVID-19 weekly epidemiology report: 28 November to December 04 2021 (week 48)
- Vaccine coverage: This report was last updated on December 17, 2021 with data up to and including December 11, 2021.
  - 87% of the population 12 years and older are fully vaccinated
  - 31.59% of the population 5 to 11 years have received at least one dose
- COVID-19 and deaths in older Canadians: Excess mortality and the impacts of age and comorbidity [12-14-2021]
- COVID-19: summary data about travellers, testing and compliance [updated 12-13-2021]
- Social inequalities in COVID-19 deaths in Canada [12-10-2021]
- Mathematical modelling and COVID-19 [updated regularly]
- COVID-19 daily epidemiology update [updated regularly]
- COVID-19 data trends [updated regularly]

BC Centre for Disease Control | bccdc.ca

- Immunization Manual
  - Summary of changes: admin circular [updated 12-15-2021]
  - COVID-19 vaccine eligibility [updated 12-15-2021]
  - COVID-19 mRNA vaccine Comirnaty® (Pfizer-BioNTech) pediatric [updated 12-15-2021]
  - COVID-19 vaccine ChAdOx1-S [recombinant] Vaxzevria™/COVISHIELD (AstraZeneca/Verity pharmaceuticals) [updated 12-15-2021]
- Vaccinated staff: variance of the facility staff assignment order [updated 12-15-2021]
- Immunize BC SOP: Pfizer pediatric redistribution guidelines [updated 12-15-2021]
- HealthLinkBC file for COVID-19 mRNA vaccines [12-14-2021]
- HealthLinkBC file for COVID-19 viral vector vaccines [12-14-2021]
- PHO’s epidemiology and modelling COVID-19 December update [12-14-2021]
- Food and liquor serving premises [updated 12-13-2021]

Institut national de santé publique | inspq.qc.ca

- Revue rapide de la littérature et données épidémiologiques provinciales de la COVID-19 parmi les jeunes âgés de moins de 18 ans [12-17-2021]
- Pertinence d’une dose de rappel d’un vaccin contre la COVID 19 pour les différentes catégories d’adultes au Québec [12-17-2021]
- Gestion des cas de COVID-19 présentant un premier test d’amplification des acides nucléiques (TAAN) avec un résultat « détecté » ou « détecté faible quantité d’ARN viral » et de leurs contacts [12-16-2021]
- Sommaire sur la vigie des manifestations cliniques inhabituelles après la vaccination contre la COVID-19 au Québec déclarées dans le cadre de la surveillance passive [12-16-2021]
- Prise en charge des personnes considérées rétablies et présentant à nouveau un test positif pour le SRAS-CoV-2 [12-16-2021]
- COVID-19 : Processus de collecte, de désinfection et d’entreposage des appareils de protection respiratoire N95 à usage unique [12-16-2021]
- Réutilisation des respirateurs N95 dans un contexte d’une pénurie réelle ou appréhendée lors de la pandémie de la COVID-19 [12-16-2021]
- SRAS-CoV-2 : Utilisation des appareils de protection respiratoire en élastomère réutilisables dans un contexte de pénurie d’APR N95 à usage unique lors de la pandémie de COVID-19 dans les milieux de soins [12-16-2021]
- COVID-19 : Désinfection des appareils de protection respiratoires N95 à usage unique [12-16-2021]
- SRAS-CoV-2 : Mesures exceptionnelles pour les équipements de protection individuelle en situation de pénurie lors de pandémie [12-16-2021]
- COVID-19 : Désinfection des protections oculaires à usage unique [12-16-2021]
- COVID-19 : Évaluation des options de désinfection des appareils de protection respiratoire N95 dans le contexte de la pandémie [12-16-2021]
- COVID-19 (SRAS-CoV-2) : Recommandations intérimaires pour la protection des travailleurs immunosupprimés [12-16-2021]
- Faits saillants du 14 décembre 2021 - Sondages sur les attitudes et comportements des adultes québécois [12-14-2021]
- Pandémie et vaccination - résultats du 14 décembre 2021 [12-14-2021]
- Pandémie et pratique d’activité physique - Résultats du 14 décembre 2021 [12-14-2021]

International (outside of Canada)

**CDC: Centers for Disease Control and Prevention | cdc.gov**

- **COVID Data Tracker weekly review** [12-17-2021]
  - In recent weeks, COVID-19 cases and hospitalizations have increased, with many parts of the country experiencing substantial or high levels of community transmission. These increases and the recent emergence of the Omicron variant highlight the importance of prevention strategies to help people stay safe and reduce the spread of the virus that causes COVID-19.
  - The current 7-day moving average of daily new cases (122,297) increased 1.5% compared with the previous 7-day moving average (120,445). A total of 50,479,372 COVID-19 cases have been reported in the United States as of December 15, 2021. Currently two variants, Omicron and Delta, are classified as Variants of Concern (VOC) in the United States. CDC’s COVID Data Tracker shows that the proportion of the Omicron variant circulating in the United States is predicted to increase from last week. Delta remains the predominant variant in the United States. Nowcast projections* for the
week ending December 11, 2021, predict the national proportion of Omicron to be 2.9% and Delta to be 96.7%. The proportion of Omicron is predicted to be higher than the national proportion in HHS regions 2 and 7. The proportions of Delta are predicted to be greater than 86% in all HHS regions.

- CDC’s COVID Data Tracker Vaccination Demographic Trends tab shows vaccination trends by age group. As of December 16, 2021, 95.0% of people ages 65 years or older have received at least one dose of vaccine and 87.3% are fully vaccinated. More than three-quarters (84.7%) of people ages 18 years or older have received at least one dose of vaccine and 72.3% are fully vaccinated. For people ages 12 years or older, 82.7% have received at least one dose of vaccine and 70.5% are fully vaccinated. For people ages 5 years or older, 76.9% have received at least one dose of vaccine and 65.1% are fully vaccinated.

- **EARLY RELEASE: Evaluation of test to stay strategy on secondary and tertiary transmission of SARS-CoV-2 in K–12 schools** — Lake County, Illinois, August 9–October 29, 2021 [12-17-2021]
- **EARLY RELEASE: Evaluation of a test to stay strategy in transitional kindergarten through grade 12 schools** — Los Angeles County, California, August 16–October 31, 2021 [12-17-2021]
- **Test-to-stay options can help keep students in school during COVID-19** [updated 12-17-2021]
- **Frequently asked questions about COVID-19 for school administrators** [updated 12-17-2021]
- **Parents and caregivers - what is your school doing to protect your child from COVID-19?** [updated 12-17-2021]
- **What you should know about COVID-19 testing in schools** [updated 12-17-2021]
- **Science brief: transmission of SARS-CoV-2 in K–12 schools** [updated 12-17-2021]
- **Science briefs** [updated 12-17-2021]
- **Schools and childcare programs** [updated 12-17-2021]
- **CDC endorses ACIP’s updated COVID-19 vaccine recommendations** [12-16-2021]
- **Cases in the U.S.** [12-16-2021]
- **Notes from the field: COVID-19–associated mucormycosis** — Arkansas, July–September 2021 [12-16-2021]
- **Notes from the field: mucormycosis cases during the COVID-19 pandemic** — Honduras, May–September 2021 [12-16-2021]
- **Booster and additional primary dose COVID-19 vaccinations among adults aged ≥65 years** — United States, August 13, 2021–November 19, 2021 [12-16-2021]
- **SARS-CoV-2 B.1.1.529 (Omicron) variant** — United States, December 1–8, 2021 [12-16-2021]
- **COVID-19 forecasts: deaths** [updated 12-15-2021]
- **Previous COVID-19 forecasts: hospitalizations** [updated 12-15-2021]
- **COVID-19 forecasts: cases** [updated 12-15-2021]
- **Information about the Moderna COVID-19 vaccine** [updated 12-14-2021]
- **Providing spiritual and psychosocial support to people with COVID-19 at home (non-US settings)** [updated 12-14-2021]
- **People with certain medical conditions** [updated 12-14-2021]
- **Guidance for SARS-CoV-2 point-of-care testing** [updated 12-13-2021]
- **COVID-19 vaccination for essential workers** [updated 12-14-2021]
- **COVID-19 vaccines for people with underlying medical conditions** [updated 12-14-2021]
- **Reporting COVID-19 vaccinations in the United States** [updated 12-14-2021]
Interim laboratory biosafety guidelines for handling and processing specimens associated with coronavirus disease 2019 (COVID-19) [updated 12-13-2021]

ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu

- Communicable diseases threat report, 12-18 December 2021, week 50 [12-17-2021]
- Weekly COVID-19 country overview [12-16-2021]
  - At the end of week 49 (week ending Sunday 12 December 2021), the overall epidemiological situation in the EU/EEA is characterised by a high overall case notification rate and a slowly increasing death rate. Increasing case notification rates and an epidemiological situation of high or very high concern are now observed, particularly in western and northern parts of the EU/EEA. This situation is largely driven by the high transmissibility of the Delta variant, which has limited the reduction in transmission achieved by the COVID-19 vaccination roll-out in the EU/EEA.
  - The overall COVID-19 case notification rate for the EU/EEA was 783.7 per 100,000 population (809.1 the previous week). This rate has been decreasing for one week. The 14-day COVID-19 death rate (58.8 deaths per million population, compared with 55.8 deaths the previous week) has been stable for three weeks. Of 29 countries with data on hospital or ICU admissions or occupancy up to week 49, 12 reported an increasing trend in at least one of these indicators compared to the previous week.
- Epidemiological update: Omicron variant of concern (VOC) – data as of 16 December 2021 (12:00) [12-16-2021]
- Infographic: COVID-19 vaccination in the EU/EEA as of 12 December 2021 [12-16-2021]
- ECDC publishes new risk assessment on further emergence of Omicron variant [12-15-2021]
- Assessment of the further emergence of the SARS-CoV-2 Omicron VOC in the context of the ongoing Delta VOC transmission in the EU/EEA, 18th update [12-15-2021]
- Epidemiological update: Omicron variant of concern (VOC) – data as of 15 December 2021 (12:00) [12-15-2021]
- Generic protocol for COVID-19 vaccine effectiveness studies during outbreaks in semi-closed settings in the EU/EEA [12-14-2021]
- Data on COVID-19 in the EU/EEA [updated regularly]

FDA: U.S. Food & Drug Administration | fda.gov

- Coronavirus (COVID-19) update: daily roundup [updated regularly]
- Fact sheet for healthcare providers administering vaccine (vaccination providers): emergency use authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) [updated 12-14-2021]
- Fact sheet for recipients and caregivers emergency use authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) in individuals 18 years of age and older [updated 12-14-2021]

Public Health England | gov.uk

Note: Public Health England was replaced by UK Health Security Agency and Office for Health Improvement and Disparities. These organizations are listed below under “Other relevant government organizations”.

- Location of Public Health England (PHE) functions from 1 October 2021
World Health Organization | who.int

- Infection prevention and control (IPC) in health-care facilities in the event of a surge or resurgence in cases of COVID-19 [12-17-2021]
- WHO lists 9th COVID-19 vaccine for emergency use with aim to increase access to vaccination in lower-income countries [12-17-2021]
- Interim recommendations for heterologous COVID-19 vaccine schedules [12-16-2021]
- Dr Ayoade Alakija appointed WHO Special Envoy for the ACT-Accelerator [12-16-2021]
- Acknowledgements: The Unity Studies for sero-epidemiological investigation of COVID-19 [12-14-2021]
- WHO Director-General’s opening remarks at the media briefing on COVID-19 [12-14-2021]
  - “Omicron is spreading at a rate we have not seen with any previous variant. We’re concerned that people are dismissing Omicron as mild. Surely, we have learned by now that we underestimate this virus at our peril. Even if Omicron does cause less severe disease, the sheer number of cases could once again overwhelm unprepared health systems. I need to be very clear: vaccines alone will not get any country out of this crisis. Countries can – and must – prevent the spread of Omicron with measures that work today. It’s not vaccines instead of masks. It’s not vaccines instead of distancing. It’s not vaccines instead of ventilation or hand hygiene. Do it all. Do it consistently. Do it well.”

- Coronavirus disease (COVID-19) weekly epidemiological update [12-14-2021]
- Coronavirus disease (COVID-19) weekly operational update [12-13-2021]
- Log of major changes and errata in WHO daily aggregate case and death count data [updated regularly]
- Draft landscape and tracker of COVID-19 candidate vaccines [updated regularly]
- Coronavirus disease (COVID-19) press briefings [audio posted first; transcripts posted later]
- Timeline: WHO’s COVID-19 response [updated regularly]
- EPI-WIN: WHO information network for epidemics [updated regularly]

Other relevant government bodies / health care organization

- Government of Ontario
  - Ontario expanding specialized COVID-19 vaccine supports for Indigenous communities [12-17-2021]
  - Ontario launching holiday pop-up testing blitz [12-16-2021]
  - All Ontarians 18+ eligible for COVID-19 booster appointments at three-month interval [12-15-2021]

- Department of Finance Canada
  - Protecting our recovery by finishing the fight against COVID-19 [updated 12-14-2021]

- Health Canada
  - Public service occupational health program COVID-19 guidance [updated 12-16-2021]

- Indigenous Services Canada
  - Coronavirus (COVID-19) and Indigenous communities [updated regularly]
  - Epidemiological summary of COVID-19 cases in First Nations communities [updated 12-16-2021]

- Statistics Canada
  - COVID-19: a data perspective [updated regularly]

- Treasury Board of Canada Secretariat
o President of the Treasury Board statement further to the evolving public health situation and the COVID-19 Omicron variant [12-16-2021]

- UK Health Security Agency
  o COVID-19 vaccination: Guillain-Barré Syndrome information for healthcare professionals [updated 12-17-2021]
  o National protocol for Spikevax (formerly COVID-19 Vaccine Moderna) [updated 12-17-2021]
  o COVID-19: infection prevention and control (IPC) [updated 12-17-2021]
  o The R value and growth rate [updated 12-17-2021]
  o COVID-19 vaccination: resources for schools and parents [updated 12-17-2021]
  o Guidance for contacts of people with confirmed coronavirus (COVID-19) infection who do not live with the person [updated 12-16-2021]
  o National protocol for Comirnaty® COVID-19 mRNA vaccine [updated 12-16-2021]
  o Personal protective equipment (PPE) recommendation for unpaid carers [updated 12-16-2021]
  o COVID-19: guidance for households with possible coronavirus infection [updated 12-16-2021]
  o COVID-19: arranging or attending a funeral or commemorative event [updated 12-16-2021]
  o Monitoring reports of the effectiveness of COVID-19 vaccination [updated 12-16-2021]
  o COVID-19: management of staff and exposed patients and residents in health and social care settings [updated 12-15-2021]

- UK Department of Health and Social Care
  o Antibody testing for SARS-CoV-2: key information [updated 12-17-2021]

- UK Department for Digital, Culture, Media & Sport
  o Working safely during coronavirus (COVID-19) [updated 12-15-2021]

- UK Department for Education

- UK Department for Environment, Food & Rural Affairs
  o Coronavirus (COVID-19): advice for people in England with animals [updated 12-16-2021]

- UK Department for Levelling Up, Housing and Communities
  o Coronavirus (COVID-19): Wedding and civil partnership ceremonies, receptions and celebrations [updated 12-16-2021]

- Centre for Global Infectious Disease Analysis
  o Report 49 - Growth, population distribution and immune escape of Omicron in England [12-16-2021]
  o Report 48 - The value of vaccine booster doses to mitigate the global impact of the Omicron SARS-CoV-2 variant [12-16-2021]
Uncertainty swirls around Omicron COVID-19 severity [12-17-2021]

CDC advisors recommend mRNA COVID vaccines over J&J [12-16-2021]

Novavax COVID vaccine shows 90.4% efficacy against infection [12-16-2021]

Omicron boosts COVID-19 surges in Denmark, UK [12-16-2021]

COVID-19 Scan for Dec 16, 2021: Vaccine-generated Omicron antibodies; Review of early CDC COVID-19 test errors

Lung tissue study sheds light on fast Omicron spread [12-15-2021]

US hits 800,000 COVID-19 deaths as Omicron now in 36 states [12-15-2021]

COVID mRNA vaccines lose strength against Delta over time [12-15-2021]

News Scan for Dec 15, 2021: Life-saving COVID-19 vaccination; Asymptomatic COVID infections; More H5N6 avian flu cases in China; Pakistan dengue outbreak

South Africa Omicron study finds drop in vaccine protection, fewer hospitalized [12-14-2021]

Pfizer says its pill may be effective against Omicron COVID-19 [12-14-2021]

COVID-19 much less likely in homeless housed in hotels: study [12-14-2021]

News Scan for Dec 14, 2021: COVID-19 and myocarditis; Convalescent plasma and COVID-19; United Arab Emirates MERS case; Lyme disease in Nebraska

December, 2021 Environmental Health Research Scan (with COVID-19 section) [12-15-2021]

November, 2021 Environmental Health Research Scan (with COVID-19 section)

October, 2021 Environmental Health Research Scan (with COVID-19 section)

Latest on COVID-19 [individual posts]

COVID-19 update (434): ECDC risk assessment, Australia, China, boosters, WHO [12-16-2021]

COVID-19 update (433): animal, Colombia (AT) zoo, lion, OIE [12-16-2021]


COVID-19 resources (case counts) | arcgis.com

Canada COVID-19

COVID-19 Canada Open Data Working Group | COVID-19 CODWG

COVID-19 in Canada (case count dashboard)

Johns Hopkins CCSE | systems.jhu.edu

2019-nCoV Global Cases (by Johns Hopkins CSSE) [real-time tracking]
• Resetting our response: changes needed in the US approach to COVID-19 [07-29-2020]

NextStrain| nextstrain.org
• Phylogeny of SARS-like betacoronaviruses including novel coronavirus (nCoV) [real-time tracking]
• Genomic epidemiology of novel coronavirus (nCoV) [real-time tracking]
• Genomic analysis of nCoV spread. Situation report 2020-01-30 [real-time tracking]

Guidelines and Technical documents (updated weekly)
The guidelines listings are current to 12-14-2021; posted 12-17-2021

Section I: General Guidelines
Ontario / Canada Main Page
• Ontario guidance
• Canadian guidance (federal)

Reopening/Rebuilding Guidelines
Ontario
• ON A plan to safely reopen Ontario and manage COVID-19 for the long-term [no date]
• ON COVID-19 public health measures and advice [no date]

Canada (federal) and provinces and territories (other than Ontario)
• CA COVID-19: Readiness criteria and indicators for easing restrictive public health measures [updated 05-14-2021]
• BC BC’s restart: a plan to bring us back together [11-16-2021]
• AB COVID-19 public health actions [no date]
• SK Public Health Measures [no date]
• MB Manitoba Pandemic Response System [no date]
• QC About the measures in force [no date]
• NB Living with COVID-19 [no date]
• NL Alert level system [no date]
• PEI COVID-19 (coronavirus) in Prince Edward Island [no date]
• NS Coronavirus (COVID-19): restrictions and guidance [updated regularly]
• NW Emerging wisely 2021 [no date]
• YT Forging ahead: The Yukon’s continuing response to COVID-19 [no date]
• NT Nunavut’s Path: Living with COVID-19 [no date]
• Guidance on Re-Opening Northern, Remote, Isolated, and Indigenous Communities [no date]

WHO
• Implementation guidance for assessments of frontline service readiness [07-01-2021]
• Considerations for implementing and adjusting public health and social measures in the context of COVID-19: Interim guidance [06-14-2021]
• Considerations for implementing and adjusting public health and social measures in the context of COVID-19 [11-04-2020]
• WHO COVID-19 Preparedness and Response Progress Report - 1 February to 30 June 2020 [08-03-2020]

UK
• Reopening businesses and venues in England [updated 12-14-2021]
• Coronavirus (COVID-19): guidance on the phased return of elite sport [updated 12-13-2021]
• Our plan to rebuild: the UK government’s COVID-19 recovery strategy [07-24-2020]

ECDC
• Data on country response measures to COVID-19 [updated 11-25-2021]
• Introducing a coherent European framework for tuning COVID-19 response measures [03-17-2021]

Vaccinations- General

Ontario Ministry of Health
• COVID-19 Vaccine-relevant information and planning resources [updated 12-14-2021]
• Guidance for Routine Immunization Services During COVID-19 Version 2 [10-28-2021]
• Ethical framework for COVID-19 vaccine distribution [updated 09-23-2021]

Canada (Federal)
• An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) Guidance on booster COVID-19 vaccine doses in Canada [12-03-2021]
• Summary of NACI rapid response of December 3, 2021: Guidance on booster COVID-19 vaccine doses in Canada [12-03-2021]
• Adjusting public health measures in the context of COVID-19 vaccination [modified 12-14-2021]
• NACI interim guidance on booster COVID-19 vaccine doses in Canada [10-29-2021]
• Archived: Summary of National Advisory Committee on Immunization (NACI) statement: Recommendations on the use of COVID-19 vaccines [modified 10-22-2021]
• Quick reference guide on use of COVID-19 vaccines: Overview [modified 10-13-2021]
• Planning guidance for immunization clinics for COVID-19 vaccines [09-23-2021]
• Archived: Guidance on the prioritization of initial doses of COVID-19 vaccine(s) [09-21-2021]
• Archived: Guidance for influenza vaccine delivery in the presence of COVID-19 [09-13-2021]
• For immunization providers: Interim national vaccine storage, handling and transportation guidelines for ultra-low temperature and frozen temperature COVID-19 vaccines [09-16-2021]
• COVID-19 immunization: federal, provincial and territorial statement of common principles [modified 08-11-2021]
• Health care provider vaccine tool kit. version 2 [05-07-2021]
• Planning guidance for administration of COVID-19 vaccine [12-21-2020]
• Canada’s COVID-19 immunization plan: saving lives and livelihoods [no date]
• Recommendations on the duration of the post-vaccination observation period for influenza vaccination during the COVID-19 pandemic [10-14-2020]
• Interim guidance on continuity of immunization programs during the COVID-19 pandemic [05-13-2020]

Provinces and territories (other than Ontario)

• BC COVID-19 Vaccine Eligibility [updated 12-09-2021]
• BC COVID-19 Vaccine Screening Checklist [12-07-2021]
• BC COVID-19 mRNA Vaccine Spikevax™ (Moderna) [updated 12-07-2021]
• BC Vaxzevria™/COVISHIELD (AstraZeneca/Verity Pharmaceuticals) [updated 12-07-2021]
• BC COVID-19 Vaccine ChAdOx1-S [recombinant] [updated 12-07-2021]
• BC COVID-19 mRNA Vaccine Comirnaty™ (Pfizer-BioNTech) [updated 12-07-2021]
• BC COVID-19 Vaccine Ad26.COV2.S [recombinant] (Janssen) [updated 12-07-2021]
• BC World Health Organization (WHO) emergency use authorization (EUA) qualified COVID-19 vaccines [updated 12-07-2021]
• BC Janssen Shipping, Storage and Use Guideline [updated 11-23-2021]
• BC 2021/22 Seasonal Influenza Vaccine Eligibility [10-00-2021]
• BC COVID-19 Pfizer vaccine shipping, storage, thawing and use guidelines [updated 10-15-2021]
• BC Moderna Redistribution Guidelines [updated 10-15-2021]
• BC Pfizer Redistribution Guidelines [updated 10-15-2021]
• BC Point of Care Risk Assessment (PCRA) [no date]
• BC Latex Content in Vaccines [updated 10-00-2021]
• BC COVID-19 Vaccination Status Information and Preventive Measures Order [10-06-2021]
• BC Immunization manual appendix A: informed consent (page 4) [updated 09-00-2021]
• BC Guidance for Receiving and Handling the Pfizer-BioNTech COVID-19 mRNA Vaccine (including dry ice procedures) [08-31-2021]
• BC COVID-19 vaccination: why your 2nd dose is important [updated 08-27-2021]
• BC Pfizer vaccine sub dose vial reporting [07-13-2021]
• BC Janssen Redistribution Guidelines [06-04-2021]
• BC COVID-19 Pfizer Vaccine Partial Tray ULT Distribution Guidelines [05-19-2021]
• BC Cold chain assets warranty contact information [05-05-2021]
• BC Vaccine SOP: Return of Materials to Manufacturers [04-30-2021]
• BC Vaccine SOP: Cold Chain Incident Reporting Process [04-30-2021]

WHO

• Annexes to the interim recommendations for use of the Janssen Ad26.COV2.S vaccine [12-09-2021]
• Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine [12-09-2021]
• Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19 [12-07-2021]
• Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing [12-05-2021]
• **Guidance on operational microplanning for COVID-19 vaccination** [11-16-2021]
• **Injection safety in the context of coronavirus disease (COVID-19) vaccination** [11-05-2021]
• **Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19** [11-03-2021]
• **Annexes to the interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19: Grading of evidence – Evidence to recommendations tables** [11-03-2021]
• **Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm** [10-28-2021]
• **Annexes to WHO interim recommendations for use of the COVID-19 vaccine BIBP** [10-28-2021]
• **Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac** [10-21-2021]
• **Annexes to the recommendations for use of the Sinovac-CoronaVac vaccine against COVID-19: grading of evidence, evidence to recommendation tables** [10-21-2021]
• **Coadministration of seasonal inactivated influenza and COVID-19 vaccines: interim guidance** [10-21-2021]
• **How to manage COVID-19 vaccines without VVM at vaccination service points?** [08-31-2021]
• **Training on handling, storing and transporting Pfizer BioNTech COVID-19 Vaccine COMIRNATY® (Tozinameran)** [08-04-2021]
• **Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™)** [07-30-2021]
• **Annexes to the interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience)** [07-30-2021]
• **COVID-19 vaccine introduction and deployment costing too (CVIC tool) version 2.2** [06-10-2021]
• **Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines** [06-01-2021]
• **Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19:** [06-01-2021]
• **Technical note on delayed shipments for the ChAdOx1-S [recombinant] vaccines: what are the implications for the administration of second doses?: Scientific brief** [05-26-2021]
• **Health worker communication for COVID-19 vaccination flow diagram** [05-13-2021]
• **AstraZeneca ChAdOx1-S/nCoV-19 [recombinant], COVID-19 vaccine: COVID-19 vaccine explainer** [05-10-2021]
• **AstraZeneca ChAdOx1-S [recombinant], COVID-19 vaccine** [05-10-2021]
• **Estimating COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalizations associated with laboratory-confirmed SARS-CoV-2: an evaluation using the test-negative design** [05-07-2021]
• **COVID-19 exercise programme - drills for vaccine deployment** [05-03-2021]
• **Why are there extra doses of vaccine in the vaccine vial?** [04-16-2021]
• **COVID-19 and mandatory vaccination: ethical considerations and caveats** [04-13-2021]
- Data for action: achieving high uptake of COVID-19 vaccines: interim guidance [04-01-2021]
- Immunization as an essential health service: guiding principles for immunization activities during the COVID-19 pandemic and other times of severe disruption [11-01-2020]

**CDC**

- COVID-19 vaccine booster shot [updated 12-09-2021]
- COVID-19 vaccination clinical & professional resources [updated 12-01-2021]
- Interim public health recommendations for fully vaccinated people [updated 11-19-2021]
- COVID-19 vaccination program operational guidance [updated 10-14-2021]
- Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic [updated 09-10-2021]
- Public health investigations of COVID-19 vaccine breakthrough cases: Case investigations protocol [no date]
- Interim guidance for routine and influenza immunization services during the COVID-19 Pandemic [04-15-2021]
- Expanding COVID-19 vaccine distribution to primary care providers to address disparities in immunization [04-14-2021]
- COVID-19 vaccination toolkits [04-08-2021]

**UK**

- COVID-19 vaccination programme [updated 12-14-2021]
- COVID-19 vaccination: booster dose resources [updated 12-11-2021]
- Monitoring reports of the effectiveness of COVID-19 vaccination [updated 12-10-2021]
- National protocol for Comirnaty® COVID-19 mRNA vaccine [updated 12-09-2021]
- National protocol for COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech) [updated 11-20-2021]
- COVID-19 vaccination: what to expect after vaccination [updated 11-09-2021]
- National protocol for COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant]) [10-29-2021]
- National protocol for Spikevax (formerly COVID-19 Vaccine Moderna) [10-08-2021]
- Monitoring of the effectiveness of COVID-19 vaccination [updated 09-14-2021]
- COVID-19 vaccination: blood clotting information for healthcare professionals [updated 09-03-2021]
- COVID-19 vaccination: information for healthcare practitioners [updated 08-06-2021]
- COVID-19 vaccination: vaccine product information [06-14-2021]
- COVID-19: vaccine surveillance strategy [03-29-2021]

**ECDC**

- Generic protocol for COVID-19 vaccine effectiveness studies during outbreaks in semi-closed settings in the EU/EEA [12-14-2021]
- Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA [11-11-2021]
- Facilitating COVID-19 vaccination acceptance and uptake in the EU/EEA [10-15-2021]
- Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with severe acute respiratory infection laboratory-confirmed with SARS-CoV-2, version 1.0 [10-08-2021]
• Interim public health considerations for the provision of additional COVID-19 vaccine doses [09-01-2021]
• Partial COVID-19 vaccination, vaccination following SARS-CoV-2 infection and heterologous vaccination schedule: summary of evidence [07-22-2021]
• Countering online vaccine misinformation in the EU/EEA [06-29-2021]
• Overview of EU/EEA country recommendations on COVID-19 vaccination with Vaxzevria, and a scoping review of evidence to guide decision-making [05-18-2021]
• Objectives of vaccination strategies against COVID-19 [04-23-2021]
• Interim guidance on the benefits of full vaccination against COVID-19 for transmission and implications for non-pharmaceutical interventions [04-21-2021]
• Rollout of COVID-19 vaccines in the EU/EEA: challenges and good practice [03-29-2021]
• Stress test on logistical aspects of COVID-19 vaccination deployment plans: final report [02-03-2021]
• Integrated COVID-19 response in the vaccination era [02-01-2021]
• COVID-19 vaccination and prioritisation strategies in the EU/EEA [12-22-2020]

Australia

• COVID-19 vaccination – vaccine dose policy [updated 12-14-2021]
• COVID-19 vaccination – information on COVID-19 Pfizer (COMIRNATY) vaccine [updated 12-05-2021]
• COVID-19 vaccination – ATAGI clinical guidance on COVID-19 vaccine in Australia in 2021 [updated 10-29-2021]
• COVID-19 vaccination – clinical advice on the use of a different COVID-19 vaccine as the second dose [updated 10-29-2021]
• COVID-19 vaccination – ATAGI guidance on the use of multi-dose vials for COVID-19 vaccination 10-14-2021]
• Op COVID SHIELD national COVID vaccine campaign plan [updated 08-03-2021]
• COVID-19 vaccination – updated provider kit for general practices [07-08-2021]

Vaccinations - Specific populations

Canada (Federal)

• Archived: National Advisory Committee on Immunization (NACI) rapid response: additional dose of COVID-19 vaccine in immunocompromised individuals following 1- or 2- dose primary series [12-03-2021]
• NACI rapid response: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]
• Summary of NACI rapid response of December 3, 2021: Updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]
• NACI rapid response: booster dose in long-term care residents and seniors living in other congregate settings [12-03-2021]

• National Advisory Committee on Immunization (NACI) statement: Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5 to 11 years of age [modified 11-25-2021]

• COVID-19: Recommendations for those vaccinated with vaccines not authorized by Health Canada for those staying in Canada to live, work or study [updated 10-28-2021]

• Archived: Preliminary guidance on key populations for early COVID-19 immunization [modified 09-21-2021]

• Planning for the 2021-2022 school year in the context of COVID-19 vaccination [updated 08-26-2021]

• Archived: Guidance on the prioritization of key populations for COVID-19 immunization [02-12-2021]

Provinces and territories (other than Ontario)

• BC COVID-19 mRNA vaccine Comirnaty™ (Pfizer-BioNTech) adult/adolescent [updated 12-08-2021]

• BC COVID-19 vaccines for pregnant people with heart disease [updated 12-04-2021]

• BC Clinical guidance on COVID-19 vaccines for people with metabolically unstable inborn errors of metabolism (IEM) [updated 12-04-2021]

• BC Clinical guidance on COVID-19 vaccines for people with thalassemia [updated 12-04-2021]

• BC Clinical guidance on COVID-19 vaccines for people with cystic fibrosis [updated 12-04-2021]

• BC Clinical guidance on COVID-19 vaccines for people with sickle cell disease [updated 12-04-2021]

• BC Clinical guidance on COVID-19 vaccines for people with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) [updated 12-04-2021]

• BC Clinical guidance on COVID-19 vaccines for persons with autoimmune rheumatic diseases updated [12-04-2021]

• BC Clinical guidance on COVID-19 vaccines for persons with inflammatory bowel disease [updated 12-04-2021]

• BC Clinical guidance on COVID-19 vaccines for people with kidney disease (dialysis, non-dialysis with advanced disease, glomerulonephritis) [updated 12-04-2021]

• BC Clinical guidance on COVID-19 vaccines for solid organ transplant recipients [updated 12-04-2021]

• BC Clinical guidance on COVID-19 vaccines for people with splenectomy or functional asplenia [updated 12-04-2021]

• BC Clinical guidance on COVID-19 vaccines for people with hematological malignancy at any stage of treatment and/or who have undergone hematopoietic stem cell transplant or CAR-T cell therapy in the past 6 months [updated 12-04-2021]

• BC Clinical guidance on COVID-19 vaccines for people with hematological malignancy at any stage of treatment and/or who have undergone hematopoietic stem cell transplant or CAR-T cell therapy in the past 6 months [updated 12-04-2021]

• BC Clinical guidance on COVID-19 vaccines for people with solid cancers [12-04-2021]

• BC Hospital and community (health care and other services) COVID-19 vaccination status information and preventive measures PHO order [11-18-2021]
• BC Clinical guidance on COVID-19 vaccines for people with autoimmune neuromuscular disorders receiving immunosuppressive/immunomodulating therapy [09-20-2021]
• BC FAQ: providing care to pregnant patients and their newborns during the COVID-19 pandemic [06-30-2021]
• BC Clinical guidance on COVID-19 vaccines for people with significant neuromuscular conditions who require respiratory support [06-17-2021]

WHO
• Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons [10-26-2021]
• Update on WHO Interim recommendations on COVID-19 vaccination of pregnant and lactating women [06-10-2021]
• Disability considerations for COVID-19 vaccination: WHO and UNICEF policy brief, 19 April 2021 [04-26-2021]

CDC
• COVID-19 vaccine information for specific groups [updated 12-14-2021]
• COVID-19 vaccination considerations for persons with underlying medical conditions [updated 12-14-2021]
• COVID-19 vaccines for people who would like to have a baby [updated 12-06-2021]
• How to talk with parents about COVID-19 vaccination [updated 11-29-2021]
• COVID-19 vaccines for children and teens [updated 11-23-2021]
• COVID-19 vaccine equity for racial and ethnic minority groups [11-02-2021]
• Guidance for vaccinating older adults and people with disabilities: ensuring equitable covid-19 vaccine access [updated 08-26-2021]
• Guidance for vaccinating older adults and people with disabilities at vaccination sites [08-10-2021]
• Interim guidance for health departments: COVID-19 vaccination implementation for people experiencing homelessness [4-30-2021]

UK
• COVID-19 vaccination: guide for adults [updated 12-09-2021]
• COVID-19 vaccination: resources for children and young people [updated 12-02-2021]
• Interim public health considerations for COVID-19 vaccination of children aged 5-11 years [12-01-2021]
• COVID-19 vaccination: women of childbearing age, currently pregnant or breastfeeding [10-08-2021]
• Safety of COVID-19 vaccines when given in pregnancy [04-30-2021]

ECDC
• Data collection on COVID-19 outbreaks in closed settings with a completed vaccination programme: long-term care facilities [09-03-2021]
• Interim public health considerations for COVID-19 vaccination of adolescents in the EU/EEA [06-01-2021]

Australia
• COVID-19 vaccination – COVID-19 vaccination decision guide for women who are pregnant, breastfeeding or planning pregnancy [updated 12-15-2021]
• ATAGI expanded guidance on temporary medical exemptions for COVID-19 vaccines [updated 11-26-2021]
- **COVID-19 vaccination – vaccine dose policy- aged cared facilities** [updated 11-08-2021]
- **ATAGI – COVID-19 vaccination – Shared decision making guide for people with immunocompromise** [updated 10-29-2021]
- **ATAGI – Provider guide to COVID-19 vaccination of people with immunocompromise** [updated 10-29-2021]
- **ATAGI clinical guidance on replacement doses for invalid primary courses of COVID-19 vaccines** [updated 10-01-2021]
- **COVID-19 vaccination – shared decision making guide for people receiving palliative care or end-of-life care** [updated 09-23-2021]
- **COVID-19 vaccination – COVID-19 vaccination decision guide for frail older people, including those in residential aged care facilities** [updated 09-23-2021]
- **COVID-19 vaccination – COVID-19 vaccine information for the residential aged care workforce** [updated 08-20-2021]

**Vaccinations- Adverse Effects**

**Canada (Federal)**
- National Advisory Committee on Immunization (NACI): rapid response: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]
- Reports of myocarditis and pericarditis after COVID-19 vaccination: Communiqué to health practitioners (June 3, 2021) [06-14-2021]

**Provinces and territories (other than Ontario)**
- BC Guidance document on the management of inadvertent vaccine errors [12-07-2021]
- BC COVID-19 vaccine planning guide for people who are pregnant or breastfeeding [10-12-2021]
- BC Adverse event following immunization with COVID-19 vaccine case report form [10-12-2021]
- BC Myocarditis/pericarditis in association with receipt of mRNA COVID-19 vaccine [06-11-2021]
- BC Summary of AEFI reporting criteria for COVID-19 vaccination for older children, adolescents and adults [no date]
- BC Clinical care guidance on vaccine-induced immune thrombotic thrombocytopenia (VITT), also known as thrombosis with thrombocytopenia syndrome (TTS) [04-30-2021]

**CDC**
- Lab tests to collect shortly after severe allergic reaction/anaphylaxis following COVID-19 vaccination [reviewed 08-09-2021]

**WHO**
- How to manage COVID-19 vaccines without VVM at vaccination service points? [08-31-2021]
- How to monitor and report COVID-19 vaccine side effects [03-15-2021]

**UK**
- Coronavirus (COVID-19) vaccine adverse reactions [12-09-2021]
- Myocarditis and pericarditis after COVID-19 vaccination [12-07-2021]
• COVID-19 vaccination: Guillain-Barré Syndrome information for healthcare professionals [08-20-2021]
• Safety of COVID-19 vaccines when given in pregnancy [04-30-2021]

Australia
• COVID-19 vaccination – Guidance on myocarditis and pericarditis after mRNA COVID-19 vaccines [12-02-2021]
• COVID-19 vaccination – Primary care approach to thrombosis with thrombocytopenia syndrome after COVID-19 AstraZeneca vaccine [09-25-2021]

Background Information/Case Definitions

Ontario Ministry of Health
• Ontario case definition - coronavirus disease (COVID-19) [05-21-2021]

PHAC
• National case definition: coronavirus disease (COVID-19) [updated 12-10-2021]
• COVID-19 case report form [02-15-2021]

CDC
• Coronavirus disease 2019 (COVID-19) 2020 interim case definition, approved August 5, 2020 [04-16-2021]

WHO
• A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 [10-06-2021]

ECDC
• Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA [04-08-2021]
• Rapid risk assessment: increased transmission of COVID-19 in the EU/EEA and the UK – thirteenth update [10-23-2020]

UK
• COVID-19: background information [10-06-2021]
• COVID-19: epidemiology, virology and clinical features [10-06-2021]

Australia
• What you need to know about coronavirus (COVID-19) [08/11/2021]

Other
• BMJ best practice COVID-19 [updated regularly]

Laboratories

Ontario Ministry of Health
• COVID-19 provincial testing guidance update V. 14.0 [updated 11-10-2021]
• Community labs and specimen collection centres: version 3 [03-29-2020]
PHAC

- Biosafety advisory: SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2) [11-23-2021]
- Polymerase chain reaction (PCR) and cycle threshold (Ct) values in COVID-19 testing [06-10-2021]
- National polymerase chain reaction (PCR) testing indication guidance for COVID-19 [10-07-2020]
- Requirements for serological antibody tests submitted under the COVID-19 interim order: guidance [04-28-2020]

WHO

- Acknowledgements: The Unity Studies for sero-epidemiological investigation of COVID-19 [12-14-2021]
- Operational considerations to expedite genomic sequencing component of GISRS surveillance of SARS-CoV-2 [03-30-2021]
- Laboratory biosafety guidance related to coronavirus disease (COVID-19) [01-28-2021]
- COVID-19 new variants: knowledge gaps and research [01-12-2021]
- Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health [01-08-2021]
- SARS-CoV-2 genomic sequencing for public health goals [01-08-2021]
- SARS-CoV-2 antigen-detecting rapid diagnostic tests: an implementation guide [12-21-2020]
- Assessment tool for laboratories implementing SARS-CoV-2 testing [10-23-2020]
- Diagnostic testing for SARS-CoV-2: interim guidance [09-11-2020]
- Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays [09-11-2020]

CDC

- Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19) [updated 12-13-2021]
- Guidance for SARS-CoV-2 point-of-care and rapid testing [updated 12-13-2021]
- Testing strategies for SARS-CoV-2 [updated 12-07-2021]
- Frequently asked questions on COVID-19 testing for laboratories [updated 11-12-2021]
- How to report COVID-19 laboratory data [updated 11-03-2021]
- Science Brief: SARS-CoV-2 infection-induced and vaccine-induced immunity [10-29-2021]
- Interim laboratory biosafety guidelines for handling and processing specimens associated with coronavirus disease 2019 (COVID-19) [10-28-2021]
- Interim guidelines for collecting, handling, and testing clinical specimens for COVID-19 [10-25-2021]
- Evaluation for SARS-CoV-2 testing in animals [10-12-2021]
- Interim guidelines for COVID-19 antibody testing: interim guidelines for COVID-19 antibody testing in clinical and public health settings [updated 09-21-2021]
- Using antibody tests for COVID-19 [updated 09-10-2021]
- Guidance for general laboratory safety practices during the COVID-19 pandemic [updated 08-19-2021]
• Lab tests to collect shortly after severe allergic reaction/anaphylaxis following COVID-19 vaccination [reviewed 08-09-2021]
• Interim guidance for use of pooling procedures in SARS-CoV-2 diagnostic and screening testing [updated 06-30-2021]
• Guidance for reporting SARS-CoV-2 sequencing results [06-23-2021]
• Genomic Surveillance for SARS-CoV-2 variants [06-17-2021]
• Resources for laboratories working on coronavirus (COVID-19) [03-28-2021]
• Information for laboratories about coronavirus (COVID-19) [03-28-2021]
• SARS-CoV-2 viral culturing at CDC [12-29-2020]
• Serology testing for COVID-19 at CDC [11-03-2020]

UK
• Protocol for evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices) [updated 12-01-2021]
• Technical validation protocol for SARS-CoV-2 nucleic acid detection [updated 12-01-2021]
• National standardised test performance process for manufacturers of SARS-CoV-2 virus antibody tests [updated 12-01-2021]
• Outcome of the evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices) [updated 12-01-2021]
• NHS test and trace statistics (England): methodology [updated 11-18-2021]
• How tests and testing kits for coronavirus (COVID-19) work [11-11-2021]
• Coronavirus (COVID-19) testing in adult care homes [updated 09-29-2021]
• Surge testing for new coronavirus (COVID-19) variants [updated 08-16-2021]
• Maintaining records of staff, customers and visitors to support NHS Test and Trace [07-20-2021]
• COVID-19: guidance for sampling and for diagnostic laboratories [03-29-2021]

ECDC
• The use of antibody tests for SARS-COV-2 in the context of Digital Green Certificates [05-10-2021]

Australia
• PHLN guidance on laboratory testing for SARS-CoV-2 (the virus that causes COVID-19) [11-02-2021]

Other
• BC PHO order on health authority regulated health professionals SARS-CoV-2 swabbing [11-16-2020]
• BC PHO order on midwives and certified practice speech language pathologists SARS-CoV-2 swabbing [11-16-2020]
• BC PHO order on British Columbia emergency health services SARS-CoV-2 swabbing [11-16-2020]
Miscellaneous Guidelines

PHAC
- Individual and community-based measures to mitigate the spread of COVID-19 in Canada [modified 12-14-2021]
- COVID-19: Safety advice for private indoor gatherings [12-09-2021]
- Federal/provincial/territorial public health response plan for ongoing management of COVID-19 [09-16-2021]
- COVID-19 and people with disabilities in Canada [06-21-2021]

Canadian provinces and territories (other than Ontario)
- BC COVID-19 ethical decision-making framework [12-24-2020]

WHO
- WHO technical consultation on oxygen access scale-up for COVID-19 [07-14-2021]
- Modelling the health impacts of disruptions to essential health services during COVID-19: Module 1: Understanding modelling approaches for sexual, reproductive, maternal, newborn, child and adolescent health, and nutrition [07-09-2021]
- Considerations in adjusting public health and social measures in the context of COVID-19: interim guidance [06-14-2021]
- WHO-convened global study of origins of SARS-CoV-2: China Part [03-30-2021]
- Practical actions in cities to strengthen preparedness for the COVID-19 pandemic and beyond [07-17-2020]
- Investing in and building longer-term health emergency preparedness during the COVID-19 pandemic [07-06-2020]
- Considerations on Indigenous Peoples, Afro-Descendants, and other ethnic groups during the COVID-19 Pandemic, 4 June 2020 [06-04-2020]
- Policy brief: COVID-19 and people on the move [06-00-2020]

CDC
- Public health guidance for potential COVID-19 exposure associated with travel [12-02-2021]
- Return to work criteria for healthcare personnel with SARS-CoV-2 infection (interim guidance) [updated 09-10-2021]
- RRT composition: COVID-19 considerations [03-01-2021]
- Public health guidance for community-related exposure [03-01-2021]
- Wildfire smoke and COVID-19: frequently asked questions and resources for air resource advisors and other environmental health professionals [10-09-2020]
- Managing investigations during an outbreak [07-31-2020]
- Optimizing supply of PPE and other equipment during shortages [07-16-2020]

ECDC
COVID-19 – high risk shielded patient list identification methodology, Version 12 [12-08-2021]
One-day in-action review (IAR) protocol in the context of COVID-19 [03-00-2021]
Behavioural Insights research to support the response to COVID-19: a survey of implementation in the EU/EEA [02-17-2021]
Conducting in-action and after-action reviews of the public health response to COVID-19 [06-04-2020]

Australia
CDNA National guidelines for public health units [updated 12-09-2021]

Other
Public health ethics and COVID-19: selected resources – National Collaborating Centre for Healthy Public Policy [11-30-2021]

Data & Surveillance

Canada
COVID-19 data trends [modified 12-10-2021]
Mathematical modelling and COVID-19 [modified 12-10-2021]
National surveillance guidelines for coronavirus disease (COVID-19) [03-19-2021]

WHO
Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States [12-10-2021]
WHO COVID-19 SPRP: updated appeal September 2021 - March 2022 [10-07-2021]
Guidance for surveillance of SARS-CoV-2 variants: Interim guidance, 9 August 2021 [08-09-2021]
WHO COVID-19 essential supplies forecasting tool (COVID-ESFT) [04-14-2021]
Public health surveillance for COVID-19: interim guidance [12-16-2020]
Corrigenda – maintaining surveillance of influenza and monitoring SARS-CoV-2 [12-03-2020]
Status of environmental surveillance for SARS-CoV-2 virus – scientific brief [08-07-2020]
Estimating mortality from COVID-19 [08-04-2020]
Surveillance strategies for COVID-19 human infection, Update 29 [06-05-2020]
Surveillance protocol for SARS-CoV-2 infection among health workers [05-28-2020]

CDC
Wastewater surveillance data reporting & analytics [11-08-2021]
National wastewater surveillance system (NWSS) [07-21-2021]
Wastewater surveillance testing methods [06-23-2021]
Public health interpretation and use of wastewater surveillance data [06-23-2021]
Developing a wastewater surveillance sampling strategy [06-23-2021]
Targeted wastewater surveillance at facilities, institutions, and workplaces [06-23-2021]
COVID-19 serology surveillance [03-11-2021]
- Data visualization [02-16-2021]
- Large-scale geographic seroprevalence surveys [10-02-2020]

ECDC

- Organisation of vector surveillance and control in Europe [12-13-2021]
- Surveillance of COVID-19 in long-term care facilities in the EU/EEA [11-29-2021]
- Epidemiological update: Omicron variant of concern (VOC) – data as of 29 November 2021 (12:30) [11-29-2021]
- COVID-19 variants: genomics and case numbers [updated 11-29-2021]
- Threat assessment brief: implications of the emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA [11-26-2021]
- COVID-19 surveillance guidance - Transition from COVID-19 emergency surveillance to routine surveillance of respiratory pathogens [10-18-2021]
- Guidance for representative and targeted genomic SARS-CoV-2 monitoring [05-03-2021]

UK

- COVID-19 surveillance in school KIDs (sKIDs): pre and primary schools [09-04-2020]

Variants – Omicron

Canada

- SARS-CoV-2 variants: national definitions, classifications and public health actions [12-03-2021]

Ontario Ministry of Health

- COVID-19 variant of concern Omicron (B.1.1.529): case, contact and outbreak management interim guidance [11-30-2021]

CDC

- Omicron variant: what you need to know [12-15-2021]

UK

- SARS-CoV-2 Omicron VOC: investigating and managing suspected or confirmed cases [12-02-2021]
- Guidance for investigating and managing individuals with a suspected or confirmed infection with Omicron SARS-CoV-2 variant of concern in healthcare settings [12-02-2021]

ECDC

- Assessment of the further emergence of the SARS-CoV-2 Omicron VOC in the context of the ongoing Delta VOC transmission in the EU/EEA, 18th update [12-15-2021]
- Threat assessment brief: implications of the further emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA first update [12-02-2021]
- Epidemiological update: Omicron variant of concern (VOC) – data as of 30 November 2021 (12.00) [11-30-2021]
- Threat Assessment Brief: Implications of the emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA [11-26-2021]
Testing
Canada
- Pan-Canadian COVID-19 testing and screening guidance: technical guidance and implementation plan [updated 09-08-2021]
- Interim guidance on the use of rapid antigen detection tests for the identification of SARS-CoV-2 infection [02-23-2021]
- Guidance for repeated PCR testing in individuals previously positive for COVID-19 [12-08-2020]
- National polymerase chain reaction (PCR) testing indication guidance for COVID-19 [10-07-2020]

Ontario Ministry of Health
- COVID-19 provincial testing guidance: version 14.0 [updated 11-10-2021]
- Considerations for antigen point-of-care testing. version 7.0 [updated 08-25-2021]
- Point-of-care testing use case guidance version 5.0 [updated 08-25-2021]
- COVID-19 test requisition [06-12-2021]
- Considerations for privately-initiated testing. version 3.0 [05-21-2021]
- COVID-19 guidance: considerations for rapid antigen screening. Version 2.0 [02-17-2021]
- Considerations for employer rapid antigen screening pilot [11-20-2020]
- COVID-19 surveillance testing – guidance regarding retirement homes staff and resident testing [06-09-2020]

Canadian provinces and territories (other than Ontario)
- BC Handout: rapid point-of-care screening in BC [09-00-2021]
- BC Infection prevention and control guidance for test collection and assessment centres [09-09-2021]
- BC Antibody testing (serology) page [no date]
- BC COVID-19: adult & pediatric viral testing guidelines for British Columbia [12-17-2020]
- BC Guideline for the appropriate use of SARS-CoV-2 (COVID-19) antibody (serology) testing [08-14-2020]

CDC
- Testing strategies for SARS-CoV-2 [updated 12-07-2021]
- Overview of testing for SARS-CoV-2 (COVID-19) [10-22-2021]
- CDC’s diagnostic test for COVID-19 only and supplies [10-05-2021]
- Using antibody tests for COVID-19 [09-10-2021]
- Testing guidelines for nursing homes: interim SARS-CoV-2 testing guidelines for nursing home residents and healthcare personnel [09-10-2021]
- Interim guidance on testing healthcare personnel for SARS-CoV-2 [09-10-2021]
- Interim guidance for rapid antigen testing for SARS-CoV-2 [09-09-2021]
- Guidance for health departments about COVID-19 testing in the community [updated 08-30-2021]
- CDC diagnostic tests for covid-19 [updated 08-07-2021]
- Guidance for SARS-CoV-2 point-of-care and rapid testing [12-13-2021]
- Nucleic acid amplification tests (NAATs) [06-14-2021]
- **Guidance for healthcare workers about COVID-19 (SARS-CoV-2) testing** [06-14-2021]
- **Interim guidance for SARS-CoV-2 testing in correctional and detention facilities** [06-07-2021]
- **Performing broad-based testing for SARS-CoV-2 in congregate correctional, detention, and homeless service settings** [03-29-2021]
- **SARS-CoV-2 antigen testing in long term care facilities** [01-07-2021]
- **Serology testing for COVID-19 at CDC** [11-03-2020]

### UK

- **Investigation of SARS-CoV-2 variants of concern: variant risk assessments** [updated 12-10-2021]
- **SARS-CoV-2 variants of public health interest** [updated 12-10-2021]
- **How tests and testing kits for coronavirus (COVID-19) work** [updated 11-11-2021]
- **Coronavirus COVID-19 serology and viral detection tests: technical validation reports** [12-01-2021]
- **Investigation of SARS-CoV-2 variants of concern: technical briefings** [updated 09-17-2021]
- **Investigation of SARS-CoV-2 variants of concern – variant risk assessments for SARS-CoV-2 variant, Delta, 8 July 2021** [07-16-2021]
- **Investigation of SARS-CoV-2 variants of concern – variant risk assessments for SARS-CoV-2 variant, Lambda, 8 July 2021** [07-16-2021]
- **SARS-CoV-2 variant of concern diagnostic assurance** [07-15-2021]
- **SARS-CoV-2 RNA testing: assurance of positive results during periods of low prevalence** [10-16-2020]

### ECDC

- **Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK** [10-26-2021]
- **Considerations on the use of rapid antigen detection (including self-) tests for SARS-CoV-2 in occupational settings** [05-06-2021]
- **Considerations for the use of saliva as sample material for COVID-19 testing** [05-03-2021]
- **Considerations on the use of self-tests for COVID-19 in the EU/EEA** [03-17-2021]
- **Guidance for COVID-19 quarantine and testing of travellers** [03-12-2021]
- **Methods for the detection and identification of SARS-CoV-2 variants** [03-03-2021]
- **Detection and characterisation capability and capacity for SARS-CoV-2 variants within the EU/EEA** [02-16-2021]
- **Risk assessment: SARS-CoV-2 - increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update** [02-15-2021]
- **COVID-19 testing strategies and objectives** [09-18-2020]
- **Objectives for COVID-19 testing in school settings** [08-10-2020]

### Australia

- **PHLN guidance on laboratory testing for SARS-CoV-2 (the virus that causes COVID-19)** [11-02-2021]
- **PHLN and DCNA joint statement on SARS-CoV-2 rapid antigen tests** [updated 08-23-2021]

### Symptoms/Treatment

#### Canada

- **COVID-19 for health professionals: treatments** [07-12-2021]
- **COVID-19 signs, symptoms and severity of disease: a clinician guide** [12-09-2021]
- **Non-contact infrared thermometers (NCIT)** (01-28-2021)

Ontario Ministry of Health

- COVID-19 Signage questions for businesses and organizations. version 6 [10-25-2021]
- COVID-19 reference document for symptoms v. 8.0 [updated 08-26-2021]
- COVID-19 Patient screening guidance document version 5.0 [updated 08-26-2021]

WHO

- Neurology and COVID-19: Scientific brief, 29 September 2021 [09-29-2021]
- Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts: interim guidance [08-12-2020]
- WHO Living guideline: drugs to prevent COVID-19 [03-02-2021]

Canadian provinces and territories (other than Ontario)

- BC Clinical practice guide for the use of sotrovimab in patients with COVID-19 [12-00-2021]
- BC Antimicrobial and immunomodulatory therapy in adult patients with COVID-19 [11-26-2021]
- BC Pediatric clinical guidance for COVID-19 [09-27-2021]
- BC Updated clinical guidance on multisystem inflammatory syndrome in children (MIS-C): key messages for BC clinicians [07-05-2021]
- BC Guideline for the management of the healthy newborn born to a pregnant mother/individual who is a confirmed or suspect case of COVID-19 [06-10-2021]
- BC Management considerations for an unwell and/or premature newborn who is a contact, under clinical investigation or a confirmed case of COVID-19 [06-10-2021]
- BC Delivery considerations for a newborn born to a mother/individual who is a confirmed case of, or under clinical investigation for, COVID-19 [05-27-2021]
- BC Patient screening tool for direct care interactions [05-03-2021]

CDC

- Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare providers [10-14-2021]
- Evidence used to update the list of underlying medical conditions that increase a person’s risk of severe illness from COVID-19 [updated 10-14-2021]
- Ending isolation and precautions for people with COVID-19: interim guidance [updated 09-14-2021]
- Ending home isolation for persons with COVID-19 not in healthcare settings [09-14-2021]
• **Caring for post-COVID conditions** [updated 09-07-2021]
• **Care for breastfeeding people** [06-17-2021]
• **Evaluating and caring for patients with post-COVID conditions: interim guidance** [06-14-2021]
• Clinical care quick reference for COVID-19 [05-17-2021]
• Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19) [02-16-2021]
• **Assessing risk factors for severe COVID-19 illness** [11-30-2020]
• Interim guidance for implementing home care of people not requiring hospitalization for coronavirus disease 2019 (COVID-19) [10-16-2020]

WHO

• **COVID-19 clinical management: living guidance** [11-23-2021]
• Therapeutics and COVID-19 [12-07-2021]
• Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection [07-15-2021]
• Hypertension and COVID-19 [06-17-2021]
• WHO Information note: COVID-19 considerations for tuberculosis (TB) care [05-05-2021]
• Expanding our understanding of post COVID-19 condition: report of a WHO webinar - 9 February 2021 [04-24-2021]
• WHO COVID-19 clinical care bundle [04-23-2021]
• Home care for patients with suspected or confirmed COVID-19 and management of their contacts: interim guidance [08-13-2020]

US NIH

• **COVID-19 treatment guidelines** [10-27-2021]

UK

• **COVID-19: migrant health guide** [updated 11-15-2021]
• **COVID-19: long-term health effects** [04-30-2021]
• SARS-CoV-2 VOC and VUI: investigating and managing individuals with a possible or confirmed case [03-15-2021]

Australia

• Coronavirus (COVID-19) – identifying the symptoms [last updated 11-11-2020]

### COVID-19 Diagnosis in Children

Canada

• **COVID-19 signs, symptoms and severity of disease: multisystem inflammatory syndrome - children (MIS-C)** [modified 12-09-2021]

Ontario

• Appendix 8: cases with positive COVID-19 serology results and management of cases with multisystem inflammatory syndrome in children (MIS-C) temporally associated with COVID-19 [02-18-2021]

CDC
- Information for healthcare providers about multisystem inflammatory syndrome in children (MIS-C) [05-20-2021]
- Information for pediatric healthcare providers [12-30-2020]
- Evaluation and management considerations for neonates at risk for COVID-19 [12-08-2020]

Other
- BC Children with immune compromise [11-30-2021]
- BC Pediatric clinical guidance for COVID-19 [09-27-2021]
- BC Guidance for newborn care, resuscitation procedures and lactation [06-11-2021]
- BC Management of severe respiratory illness in pediatric patients during the COVID-19 pandemic [05-12-2021]

Post-COVID-19 Condition
Canada
- Post COVID-19 condition [09-24-2021]

Ontario
- Science Table Understanding the post COVID-19 condition (long COVID) and the expected burden for Ontario [09-14-2021]

WHO
- Evaluating and caring for patients with post-COVID conditions: interim guidance [06-14-2021]
- Expanding our understanding of post COVID-19 condition: report of a WHO webinar - 9 February 2021 [04-24-2021]

CDC
- Caring for post-COVID conditions [09-07-2021]
- Post-COVID conditions: information for healthcare providers [07-09-2021]
- Evaluating and caring for patients with post-COVID conditions: interim guidance [06-14-2021]

UK
- COVID-19: long-term health effects [04-30-2021]

Case Investigation & Contact Tracing
Canada
- Public health management of cases and contacts associated with COVID-19 [11-02-2021]

Ontario
- COVID-19 fully immunized and previously positive individuals: case, contact and outbreak management interim guidance v 3 [10-12-2021]
- Management of cases and contacts of COVID-19 in Ontario (version 13.0) [08-11-2021]
- Appendix 11: high risk contact flow chart [no date]
• Appendix 9: management of individuals with point-of-care results version 6.0 [08-25-2021]
• Appendix 8: cases with positive COVID-19 serology results and management of cases with multisystem inflammatory syndrome in children (MIS-C) temporally associated with COVID-19 [02-18-2021]
• Appendix 10: case & contact management COVID-19 surge support model (pilot) [01-21-2021]

Canadian provinces and territories (other than Ontario)
• BC Interim guidance: public health management of cases and contacts associated with novel coronavirus (COVID-19) in the community [07-16-2021]

WHO
• Considerations for quarantine of contacts of COVID-19 cases [06-25-2021]
• Operational guide for engaging communities in contact tracing [05-28-2021]
• Contact tracing in the context of COVID-19 [02-01-2021]
• Online global consultation on contact tracing for COVID-19, 9-11 June 2020 [01-22-2021]
• Ethical considerations to guide the use of digital proximity tracking technologies for COVID-19 contact tracing [05-28-2020]

CDC
• Quarantine and isolation [12-09-2021]
• COVID-19 Contact tracing communications toolkit for health departments [11-05-2021]
• Considerations for case investigation and contact tracing in K-12 schools and institutions of higher education (IHEs) [10-19-2021]
• Contact tracer’s interview tool: notifying people about an exposure to COVID-19 [10-19-2021]
• Contact tracing resources for health departments [09-23-2021]
• Operational considerations for adapting a contact tracing program to respond to the COVID-19 pandemic in non-US Settings [09-22-2021]
• Ending home isolation for persons with COVID-19 not in healthcare settings [09-14-2021]
• Contact Tracing for COVID-19 [02-25-2021]
• Prioritizing case investigations and contact tracing for covid-19 in high burden jurisdictions [02-19-2021]
• Interim guidance on developing a covid-19 case investigation & contact tracing plan: overview [02-18-2021]
• Scaling up staffing roles in case investigation and contact tracing [12-03-2020]
• Prioritizing COVID-19 contact tracing mathematical modeling methods and findings [11-23-2020]
• Investigating a COVID-19 case [11-23-2020]
• Digital contact tracing tools [05-26-2020]

UK
• COVID-19: guidance for households with possible coronavirus infection [updated 12-14-2021]
• Guidance for contacts of people with confirmed coronavirus (COVID-19) infection who do not live with the person [updated 12-14-2021]
• COVID-19: investigation and initial clinical management of possible cases [12-14-2020]

ECDC
- **Contact tracing in the European Union: public health management of persons, including healthcare workers, who have had contact with COVID-19 cases – 4th update** [10-28-2021]
- **Indicator framework to evaluate the public health effectiveness of digital proximity tracing solutions** [06-28-2021]
- **Considerations relating to passenger locator data, entry and exit screening and health declarations in the context of COVID-19 in the EU/EEA and the UK** [06-12-2020]
- **Mobile applications in support of contact tracing for COVID-19 - A guidance for EU EEA Member States** [06-10-2020]

### Infection Prevention and Control

**PHAC / Health Canada**

- [Coronavirus disease (COVID-19): prevention and risks](https://example.com) [modified 12-14-2021]
- [COVID-19 medical masks and N95 respirators: overview](https://example.com) [updated 11-29-2021]
- [Infection prevention and control for COVID-19: interim guidance for acute healthcare settings](https://example.com) [11-02-2021]
- [Infection prevention and control for COVID-19: interim guidance for home care settings](https://example.com) [modified 11-02-2021]
- [Infection prevention and control for COVID-19: interim guidance for outpatient and ambulatory care settings](https://example.com) [11-02-2021]
- [At home: using ventilation and filtration to reduce the risk of aerosol transmission of COVID-19](https://example.com) [09-22-2021]
- [Federal/provincial/territorial public health response plan for ongoing management of COVID-19](https://example.com) [09-16-2021]
- [Evaluating COVID-19 disease transmission and public health measures in schools: outbreak investigation guidance](https://example.com) [08-18-2021]
- [COVID-19: guidance on indoor ventilation during the pandemic](https://example.com) [01-18-2021]

**Ontario**

- [Infection Prevention and Control Hubs](https://example.com) [11-10-2020]

**Canadian provinces and territories (other than Ontario)**

- **BC** [COVID-19 infection prevention and control: guidance for home and community health-care](https://example.com) [11-30-2021]
- **BC** [Infection prevention and control guidance on SARS-CoV-2 variants of concern](https://example.com) [10-12-2021]
- **BC** [Infection prevention and control (IPC) protocol during in-hospital Code Blue for adult patients](https://example.com) [09-27-2021]
- **BC** [Discussion on risk of SARS-CoV-2 aerosol transmission in health care settings](https://example.com) [09-08-2021]
- **BC** [Infection prevention and control guidance for community-based physicians, nursing professionals and midwives in clinic settings](https://example.com) [09-01-2021]
- **BC** [Infection prevention and control policy for all health authorities](https://example.com) [09-01-2021]
- **BC** [Infection prevention and control guidance for long-term care and seniors' assisted living settings](https://example.com) [08-30-2021]
- **BC** [Infection prevention and control: guidance for acute health-care settings](https://example.com) [08-30-2021]
• BC Environmental cleaning and disinfectants for clinic settings poster [06-02-2021]
• BC PPE audit tool [03-19-2021]
• BC COVID-19: personal protective equipment recommendations for endotracheal intubation of suspected or confirmed COVID-19 patients in critical care and emergency departments [01-14-2021]
• QC Support document for the Advisory Committee on COVID-19 transmission in school and healthcare environments and on the role of ventilation [09-08-2021]
• QC FAQ: COVID-19 transmission modes and measures to prevent and control risk, including the role of ventilation [no date]
• QC COVID-19: Use of air conditioners and electric fans during heat waves [08-04-2021]
• QC SARS-CoV-2 transmission: findings and proposed terminology [07-09-2021]
• QC COVID 19: surface cleaning and disinfection [06-14-2021]
• QC Aerosol-generating medical interventions on suspected and confirmed cases of COVID-19 [03-17-2021]
• QC COVID-19: infection prevention and control measures for hemodialysis units [02-26-2021]

WHO
• Annex to Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed [10-01-2021]
• Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed [07-12-2021]
• WHO COVID-19 infection prevention and control (IPC) pillar achievements. February 2020 – January 2021 [05-14-2021]
• Reducing public health risks associated with the sale of live wild animals of mammalian species in traditional food markets [04-12-2021]
• Roadmap to improve and ensure good indoor ventilation in the context of COVID-19 [03-01-2021]
• Technical specifications of personal protective equipment for COVID-19 [11-13-2020]
• Readiness for influenza during the COVID-19 pandemic [11-06-2020]
• Water, sanitation, hygiene, and waste management for SARS-CoV-2, the virus that causes COVID-19 [07-29-2020]

CDC
• Considerations for inpatient obstetric healthcare settings [11-19-2021]
• Cleaning and disinfecting your facility: every day and when someone is sick [11-15-2021]
• Strategies for optimizing the supply of N95 respirators [09-16-2021]
• Strategies for optimizing the supply of eye protection [09-13-2021]
• Interim infection prevention and control recommendations to prevent SARS-CoV-2 spread in nursing homes [09-10-2021]
• Considerations for optimizing the supply of powered air-purifying respirators (PAPRs) [11-03-2020]

ECDC
• Risk of SARS-CoV-2 transmission from newly-infected individuals with documented previous infection or vaccination [03-29-2021]
• Infection prevention and control and preparedness for COVID-19 in healthcare settings- sixth update [02-09-2021]
• Coronavirus disease 2019 (COVID-19) and supply of substances of human origin in the EU/EEA - Second update [12-10-2020]
• Guidelines for the use of non-pharmaceutical measures to delay and mitigate the impact of 2019-nCoV [09-24-2020]

UK
• COVID-19: guidance for stepdown of infection control precautions and discharging COVID-19 patients from hospital to home settings [updated 12-14-2021]
• Technical specifications for personal protective equipment (PPE) [11-30-2021]
• COVID-19: infection prevention and control (IPC) [11-24-2021]
• Ventilation of indoor spaces to stop the spread of coronavirus (COVID-19) [09-15-2021]
• COVID-19: personal protective equipment use for aerosol generating procedures [08-21-2020]
• COVID-19: personal protective equipment use for non-aerosol generating procedures [08-21-2020]

Australia
• CDNA guidelines for the prevention, control and public health management of COVID-19 outbreaks in correctional and detention facilities in Australia [10-07-2021]
• Coronavirus (COVID-19) guidelines for infection prevention and control in residential care facilities [06-16-2021]
• Guidance on the use of personal protective equipment (PPE) in hospitals during the COVID-19 outbreak [06-10-2021]
• ICEG guidelines on cleaning and disinfection of protective eyewear in health and residential care facilities [06-10-2021]
• CDNA national guidelines for the prevention, control and public health management of COVID-19 outbreaks in residential care facilities in Australia [updated 06-10-2021]
• CDNA national guidelines for the prevention and management of COVID-19 outbreaks in disability residential services - the disability supplement [06-10-2021]

Section II: Guidelines for Health Sectors

Healthcare Providers

Ontario Ministry of Health
• COVID-19 guidance: primary care providers in a community setting: version 9.0 [10-19-2021]
Canada

- COVID-19 pandemic guidance for the health care sector: 4.3 human resources [04-22-2020]

Canadian provinces and territories (other than Ontario)

- BC Entrance screening tool for health care facilities [11-05-2021]
- BC Overview of visitors in acute care [11-01-2021]
- BC Visitor restrictions in effect poster [11-01-2021]
- BC Recommendations for risk assessment and management of health-care worker exposures to COVID-19 patients [09-22-2021]
- BC Primary care summary: what is the ethical duty of health-care workers to provide care during the COVID-19 pandemic? [09-03-2021]
- BC COVID-19 ethics analysis: intervening when patients or residents pose a risk of COVID-19 transmission to others [01-18-2021]
- BC Management of PPE-related skin damage for health care workers v1.1 [no date]

WHO

- Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19: Interim guidance [07-12-2021]
- COVID-19: Occupational health and safety for health workers [02-02-2021]

CDC

- Interim guidance for managing healthcare personnel with SARS-CoV-2 infection or exposure to SARS-cov-2 [09-10-2021]

UK

- COVID-19: management of staff and exposed patients and residents in health and social care settings [updated 12-15-2021]
- Contract tracing in the European Union: public health management of persons, including healthcare workers, who have had contact with COVID-19 cases – fourth update [10-28-2021]

First Responders, Dentistry, Pharmacy, and Allied Health

Ontario Ministry of Health


PHAC

- Evidence to support safe return to clinical practice by oral health professionals in Canada during the COVID-19 pandemic: a report prepared for the Office of the Chief Dental Officer of Canada Ontario Ministry of Health [09-21-2021]

WHO

- Maintaining a safe and adequate blood supply during the pandemic outbreak of coronavirus disease (COVID-19): interim guidance [02-17-2021]
CDC
- Evaluation for SARS-CoV-2 testing in animals [10-12-2021]
- COVID-19 considerations for school sealant programs [07-13-2021]

UK
- COVID-19: guidance for first responders [updated 12-03-2021]
- COVID-19: guidance for ambulance services [updated 11-30-2021]

Other
- COVID-19: managing infection risks during in-person dental care Royal College of Dental Surgeons of Ontario [09-20-2021]
- COVID-19: guidance for the use of teledentistry Royal College of Dental Surgeons of Ontario [no date]

Death Services
Ontario
- ON Bereavement Authority of Ontario COVID-19 [10-27-2021]

Canada
- Interim guidance: death care services and handling of dead bodies during the coronavirus disease (COVID-19) pandemic [09-23-2020]
- Interim guidance: management of mass fatalities during the coronavirus disease (COVID-19) pandemic [04-25-2020]

WHO
- Infection prevention and control for the safe management of a dead body in the context of COVID-19: interim guidance [09-04-2020]

CDC
- Recommendations for Tribal ceremonies & gatherings [09-30-2021]
- Collection and submission of postmortem specimens from deceased persons with known or suspected COVID-19: interim guidance [12-02-2020]
- FAQs for medicolegal death investigators [11-02-2020]

UK
- COVID-19: guidance for arranging or attending a funeral or commemorative event [updated 12-14-2021]
- COVID-19: guidance for care of the deceased [10-11-2021]

Other
- QC COVID-19: preventive and protective measures for funeral services businesses [07-30-2021]
Congregate Living (including Long-Term Care, Prisons, and Shelters)

Ontario Ministry of Health

- COVID-19 guidance: congregate living for vulnerable populations [11-29-2021]
- COVID-19 screening tool for long-term care homes and retirement homes: version 7 [12-09-2021]
- COVID-19 guidance: long-term care homes and retirement homes for public health units [07-23-2021]
- Retirement homes policy to implement directive #3 [07-16-2021]
- COVID-19 guidance: home and community care providers: version 6 [05-21-2021]

PHAC

- Guidance for providers of services for people experiencing homelessness (in the context of COVID-19) [09-22-2021]
- COVID-19: guidance on pets and long-term care homes [07-20-2021]
- Using ventilation and filtration to reduce aerosol transmission of COVID-19 in long-term care homes [04-12-2021]
- COVID-19 guidance for long-term care facilities and nursing homes in Indigenous communities [04-14-2020]

WHO

- Infection prevention and control guidance for long-term care facilities in the context of COVID-19 update: interim guidance [01-08-2021]

CDC

- How to protect yourself and others [updated 11-29-2021]
- Interim guidance on people experiencing unsheltered homelessness [11-04-2021]
- Interim guidance for homeless service providers to plan and respond to Coronavirus Disease 2019 (COVID-19) [11-03-2021]
- Correctional and detention facilities [10-19-2021]
- Infection control for nursing homes [09-10-2021]
- Interim guidance for general population disaster shelters during the COVID-19 pandemic [08-30-2021]
- Investigating cases in homeless shelters [08-13-2021]
- Interim guidance on management of coronavirus disease 2019 (covid-19) in correctional and detention facilities [06-09-2021]
- Recommendations for quarantine duration in correctional and detention Facilities [06-09-2021]
- Guidance for group homes for individuals with disabilities [05-17-2021]
- Interim guidance for health departments: COVID-19 vaccination implementation for people experiencing homelessness [04-30-2021]
- Performing broad-based testing for SARS-CoV-2 in congregate correctional, detention, and homeless service settings [03-29-2021]
UK

- COVID-19: guidance for hostels or day centres for people rough sleeping [updated 12-15-2021]
- COVID-19: provision of night shelters [updated 12-13-2021]
- Management of acute respiratory illness in prisons and places of detention [updated 12-10-2021]
- Coronavirus (COVID-19) and prisons [12-09-2021]
- Surveillance of COVID-19 in long-term care facilities in the EU/EEA [11-29-2021]
- Preventing and controlling outbreaks of COVID-19 in prisons and places of detention [09-09-2021]
- Data collection on COVID-19 outbreaks in closed settings with a completed vaccination programme: long-term care facilities, v. 2.0 [09-03-2021]
- COVID-19: how to work safely in domiciliary care in England [08-26-2021]
- COVID-19: National framework for prison regimes and services [08-18-2021]
- COVID-19: admission and care of people in care homes [08-17-2021]
- COVID-19: how to work safely in care homes [08-16-2021]
- COVID-19 guidance for prison settings v 1.0 [07-16-2021]
- Infection prevention and control and surveillance for coronavirus disease (COVID-19) in prisons in EU/EEA countries and the UK [07-03-2020]
- Infection control in prisons and places of detention [07-01-2011]

Canadian provinces and territories (other than Ontario)

- BC Social visiting guidelines for long term care and assisted living facilities [11-04-2021]
- BC Visitor guidance for long-term care and seniors' assisted living [10-12-2021]

Other

- CSC Testing of inmates in federal correctional institutions for COVID-19 [updated 12-14-2021]
- BC COVID-19 Infection Prevention and Control: guidance for long-term care and seniors' assisted living settings [08-30-2021]
- Australia CDNA guidelines for the prevention, control and public health management of COVID-19 outbreaks in correctional and detention facilities in Australia [10-07-2021]

Section III: Guidelines for the Community

Travel, Transport & Borders

Ontario Ministry of Health

- Travelling during COVID-19 [09-23-2021]
- Guidance for public transit agencies and passengers in response to COVID-19 [05-10-2021]

Canada

- Official global travel advisories [updated daily]
• Provincial and territorial restrictions [updated 11-26-2021]
• COVID-19: travel, testing, quarantine and borders [updated 11-27-2021]
• COVID-19: passenger transport where you may have been exposed [11-17-2021]
• Guidance material for air operators managing travellers during the check-in procedure for flights departing from an aerodrome in Canada [11-16-2021]
• Federal safety guidance to protect drivers and limit the spread of COVID-19 in commercial vehicle operations [06-24-2021]

CDC
• COVID-19 travel recommendations by destination [updated 12-13-2021]
• Required testing before air travel to the US [updated 12-02-2021]
• Travel-associated exposures [updated 12-02-2021]
• Public Health Guidance for Potential COVID-19 Exposure Associated with Travel [updated 12-02-2021]

WHO
• WHO public health checklist for controlling the spread of COVID-19 in ships, sea ports and inland ports [10-00-2021]

ECDC
• COVID-19 aviation health safety protocol: operational guidelines for the management of air passengers and aviation personnel in relation to the COVID-19 pandemic [06-17-2021]

UK
• Coronavirus (COVID-19): domestic cruise ship travel [12-14-2021]
• COVID-19: general aviation [12-14-2021]
• Coronavirus (COVID-19): testing before you travel to England [updated 12-13-2021]
• COVID-19: safer travel guidance for passengers [updated 12-10-2021]
• COVID-19: safer transport guidance for operators and people who work in or from vehicles [updated 12-10-2021]
• COVID-19: taxis and PHVs [updated 12-10-2021]
• Coronavirus (COVID-19): taxis and PHVs [updated 12-10-2021]
• Travel to England from another country during coronavirus (COVID-19) [updated 12-07-2021]
• COVID-19: safer air travel for passengers [updated 12-07-2021]
• Coronavirus (COVID-19): safer practice for international hauliers [10-11-2021]
• Coronavirus (COVID-19): safer aviation guidance for operators [07-19-2021]
• COVID-19: safer aviation guidance for operators [07-19-2021]

Other
• Emergency response plan and action checklist for use by air carriers in the event of a public health emergency [no date]
### Schools / Childcare

**Ontario Ministry of Health**
- [COVID-19: health and safety measures at schools](#) [11-26-2021]
- [COVID-19: health, safety and operational guidance for schools (2021-2022)](#) [08-26-2021]
- [COVID-19: health and safety measures for child care](#) [08-17-2021]
- [COVID-19 safety guidelines for: overnight camps, version 3.0](#) [08-12-2021]
- [COVID-19 guidance: school outbreak management](#) [08-11-2021]

**PHAC**
- [COVID-19: organized summer activities for children and youth](#) [10-04-2021]
- [Planning for the 2021-2022 school year in the context of COVID-19 vaccination](#) [08-26-2021]

**CDC**
- [COVID-19 Guidance for Operating Early Care and Education/Child Care Programs](#) [updated 11-10-2021]
- [Guidance for COVID-19 Prevention in K-12 Schools](#) [updated 11-05-2021]
- [Considerations for institutions of higher education](#) [updated 11-04-2021]
- [Schools and childcare programs](#) [11-01-2021]

**UK**
- [Higher education providers: coronavirus (COVID-19)](#) [updated 12-14-2021]
- [Managing coronavirus (COVID-19) in education and childcare settings](#) [updated 12-14-2021]
- [Transport to schools and colleges during the COVID-19 pandemic](#) [updated 12-14-2021]
- [Protective measures for holiday or after-school clubs and other out-of-school settings for children during the coronavirus (COVID-19) outbreak](#) [updated 12-14-2021]
- [Guidance for parents and carers of children attending out-of-school settings during the coronavirus (COVID-19) outbreak](#) [updated 12-14-2021]
- [Actions for schools during the coronavirus outbreak](#) [updated 12-14-2021]
- [Actions for early years and childcare providers during the coronavirus (COVID-19) outbreak](#) [updated 12-14-2021]
- [Special schools and other specialist settings: coronavirus (COVID-19)](#) [updated 12-14-2021]
- [Coronavirus (COVID-19) test kits for children's homes](#) [updated 12-10-2021]
- [What parents and carers need to know about early years providers, schools and colleges during COVID-19](#) [updated 12-10-2021]
- [Coronavirus (COVID-19): guidance for children's social care services](#) [updated 12-10-2021]
- [Providing school meals during coronavirus (COVID-19) outbreak](#) [10-05-2021]

**Other**
- [QC Support document for the advisory committee on COVID-19 transmission in school and healthcare environments and on the role of ventilation](#) [09-08-2021]

### Mental Health /Addiction /Inequity

**Ontario Ministry of Health**
- [COVID-19: mental health resources for camp operators version 1.0](#) [07-13-2021]
- [Guidance for consumption and treatment services sites: version 2](#) [04-16-2020]
- **COVID-19 Guidance: mental health and addictions service providers in community settings: version 2** [09-24-2020]

**PHAC**
- [Helping people who use substances during the COVID-19 pandemic][1] [07-06-2021]

**Provinces & Territories (excluding Ontario)**
- **AB** [Harm reduction and COVID-19: guidance document for community service providers][2] [12-08-2020]
- **QC** [COVID-19: tackling social isolation and loneliness among seniors in a pandemic context][3] [10-28-2020]
- **BC** [COVID-19: provincial episodic overdose prevention service (e-OPS) protocol][4] [06-26-2020]
- **BC** [COVID-19: harm reduction and overdose response][5] [07-08-2020]

**WHO**
- [Rise, respond, recover: renewing progress on women's, children's and adolescent's health in the era of COVID-19][6] [12-00-2021]
- [Social isolation and loneliness among older people: advocacy brief][7] [07-29-2021]
- [Smoking and COVID-19][8] [06-30-2020]
- [Addressing violence against children, women and older people during the COVID-19 pandemic: key actions][9] [06-18-2020]
- [COVID-19 and violence against women: what the health sector / system can do][10] [04-07-2020]

**CDC / SAMHSA**
- [Substance abuse and mental health training and technical assistance related to COVID-19][11] [08-16-2021]
- [Virtual recovery resources][12] [07-00-21]
- [Disaster planning handbook for behavioural health service programs][13] [03-00-2021]
- [Interim guidance for syringe services programs][14] [05-15-2020]
- [Considerations for the care and treatment of mental and substance use disorders in the COVID-19 epidemic: March 20, 2020][15] [05-07-2020]
- [Considerations for crisis centers and clinicians in managing the treatment of alcohol or benzodiazepine withdrawal during the COVID-19 epidemic: March 19, 2020][16] [03-19-2020]
- [Intimate partner violence and child abuse considerations during COVID-19][17] [no date]

**UK**
- [Domestic abuse: how to get help][18] [11-11-2021]
- [Alcohol and drug misuse prevention and treatment guidance][19] [08-11-2021]
- [Every Mind Matters: looking after your mental health][20] [no date]

**Other**
- [Public health ethics and COVID-19: selected resources][21] [11-00-2021]
- [Risk mitigation in the context of dual public health emergencies. Version 1.5][22] [03-00-20]
- [COVID-19: guidance for individuals experiencing abuse][23] York University (Ontario) [no date]
Community

Ontario Ministry of Health

- Organized social events and public gatherings [10-22-2021]
- Extra-curricular activities and community use of schools [08-26-2021]
- Guidance on community emergency evacuations: version 2 [07-06-2021]

PHAC

- COVID-19: Safety advice for private indoor gatherings [12-09-2021]
- COVID-19: plan a safe holiday or celebration [12-09-2021]
- Individual and community-based measures to mitigate the spread of coronavirus disease (COVID-19) in Canada [12-14-2021]
- COVID-19: organized summer activities for children and youth [10-04-2021]
- At home: using ventilation and filtration to reduce the risk of aerosol transmission of COVID-19 [09-22-2021]
- Reducing COVID-19 risk in community settings: A tool for operators [08-2021]

WHO

- Key planning recommendations for mass gatherings in the context of COVID-19 [11-04-2021]
- Safe Eid al Adha practices in the context of COVID-19 [07-13-2021]

CDC

- Breastfeeding & caring for newborns [updated 12-09-2021]
- Activities, Gatherings & Holidays [12-09-2021]
- Information about COVID-19, pets, and other animals [11-18-2021]
- Recommendations for Tribal ceremonies & gatherings [09-30-2021]
- Community, Work, and School [08-24-2021]
- Guidance for adult day services centers [08-12-2021]
- Interim guidance for general population disaster shelters during the COVID-19 pandemic [08-04-2021]
- Operational considerations for community isolation centers [08-09-2021]
- COVID-19 response health equity strategy: accelerating progress towards reducing COVID-19 disparities and achieving health equity [08-21-2020]
- Considerations for owners and operators of multifamily housing including populations at increased risk for complications from COVID-19 [05-05-2021]

UK

- COVID-19: guidance for providers of accommodation for asylum seekers [updated 12-14-2021]
- Coronavirus: how to stay safe and help prevent the spread [updated 12-14-2021]
- COVID-19: guidance for households with possible coronavirus infection [updated 12-14-2021]
- Guidance on coronavirus (COVID-19) measures for grassroots sport participants, providers and facility operators [12-13-2021]
- Moving home during coronavirus (COVID-19) [12-13-2021]
- COVID-19: guidance for the safe use of places of worship [12-10-2021]
- Supported living services during coronavirus (COVID-19) [11-22-2021]

Canadian provinces and territories (other than Ontario)
- QC COVID 19: Surface cleaning and disinfection [06-14-2021]
- BC Guideline for the management of the healthy newborn born to a pregnant mother/individual who is confirmed or suspect case of COVID-19 [06-10-2021]

Australia
- Early aero-medical evacuation of COVID-19 cases and contacts from remote communities [08-20-2020]

Businesses/Workplaces

Ontario Ministry of Health
- COVID-19 worker and employee screening [10-29-2021]
- COVID-19 customer screening [10-29-2021]
- COVID-19 signage questions for businesses and organizations [10-25-2021]
- COVID-19 and workplace health and safety [10-15-2021]
- Proof of vaccination guidance for businesses and organizations under the reopening act. Version 4 [11-16-2021]
- Restaurant and food services health and safety during COVID-19 [10-08-2021]
- COVID-19 guidance: workplace outbreaks v2.0 [10-05-2021]

PHAC
- Reducing COVID-19 risk in community settings: a tool for operators [08-09-2021]

WHO
- Preventing and mitigating COVID-19 at work [05-19-2021]

CDC
- Workplaces & businesses: plan, prepare and respond [10-18-2021]
- Protecting workers: guidance on mitigating and preventing the spread of COVID-19 in the workplace [updated 08-13-2021]

UK

Other
- BC Guidance on return to work for health care workers with confirmed or suspected COVID-19 [09-22-2021]
- BC Guidance for outside dining spaces based on the Provincial Health Officer’s order to food and liquor serving premises [04-23-2021]
Masks (Non-Medical)

Ontario Ministry of Health
- Face coverings and face masks [09-16-2021]

PHAC
- COVID-19 mask use: advice for community settings [updated 12-09-2021]

WH24O
- What are relevant, feasible and effective approaches to promote acceptance, uptake and adherence to physical distancing measures for COVID-19 prevention and control? [00-00-2021]
- Advice on the use of masks in the context of COVID-19 [12-01-2020]

CDC
- Your guide to masks [10-25-2021]
- Use of masks to help slow the spread of COVID-19 [08-12-2021]

ECDC
- Use of gloves in healthcare and non-healthcare settings in the context of the COVID-19 pandemic [07-02-2020]

UK
- Face coverings: when to wear one, exemptions, and how to make one [updated 12-07-2021]
- The Disabled Persons Transport Advisory Committee (DPTAC) position on face coverings [03-22-2021]

Other
- BC Face coverings (COVID-19) [updated 12-03-2021]